Ditch Labs, a Montreal-based precision medicine company, is developing a new smoking cessation system and just completed a $1.3 million round of funding.

The Montreal-based startup closed a Seed round in May 2021 with the participation of Amplify Capital, Desjardins Capital, Boreal Ventures, Anges Québec, Formentera Capital, the Healthcare innovation arm of Symphony Care Network, along with renowned tech entrepreneurs such as Cherif Habib (CEO of Dialogue) and Simon de Beane (CEO of GSoft), among others.

“Part of the problem is that current smoking cessation products seek to treat a very complex addiction with a one-size-fits-all approach. Ditch is the first solution to adapt its treatment in real-time, based on craving intensity and behavioral feedback.”
— Laurent Laferriere, co-founder & CEO, Ditch Labs